UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Latent autoimmune diabetes in adults (LADA) should be less latent

Diabetologia, 2005-11, Vol.48 (11), p.2206-2212

2005

Volltextzugriff (PDF)

NETosis‐associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count

Clinical and experimental immunology, 2016-06, Vol.184 (3), p.318-322

2016

Volltextzugriff (PDF)

In‐vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes

Clinical and experimental immunology, 2020-01, Vol.199 (1), p.50-55

2020

Volltextzugriff (PDF)

Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study

Diabetes (New York, N.Y.), 1999-01, Vol.48 (1), p.170-175

1999

Volltextzugriff (PDF)

Longitudinal monitoring of gene expression in ultra‐low‐volume blood samples self‐collected at home

Clinical and experimental immunology, 2017-05, Vol.188 (2), p.226-233

2017

Volltextzugriff (PDF)

Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients

Diabetes (New York, N.Y.), 1999-05, Vol.48 (5), p.983-988

1999

Volltextzugriff (PDF)

Immunomodulation in Type 1 Diabetes by NBI‐6024, an Altered Peptide Ligand of the Insulin B(9−23) Epitope

Scandinavian journal of immunology, 2006-01, Vol.63 (1), p.59-69

2006

Volltextzugriff (PDF)

High frequency of abnormal glucose tolerance in DQA10102/DQB10602 relatives identified as part of the Diabetes Prevention Trial-Type 1 Diabetes

Diabetologia, 2005, Vol.48 (1), p.68-74

2005

Volltextzugriff (PDF)

Islet cell antibody-positive relatives with human leukocyte antigen DQA10102, DQB10602: identification by the Diabetes Prevention Trial-type 1

The journal of clinical endocrinology and metabolism, 2000-03, Vol.85 (3), p.1255-1260

2000

Volltextzugriff (PDF)

Evaluation of in vivoT cell kinetics: use of heavy isotope labelling in type 1 diabetes

Clinical and experimental immunology, 2013-06, Vol.172 (3), p.363-374

2013

Volltextzugriff (PDF)

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

The Lancet (British edition), 2013-06, Vol.381 (9881), p.1905-1915

2013

Volltextzugriff (PDF)

Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes

Clinical and experimental immunology, 2013-06, Vol.172 (3), p.363-374

2013

Volltextzugriff (PDF)

Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes

Journal of autoimmunity, 2005-11, Vol.25 (3), p.244-250

2005

Volltextzugriff (PDF)

Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

Diabetes (New York, N.Y.), 1996-11, Vol.45 (11), p.1631-1634

1996

Volltextzugriff (PDF)

Intra-islet insulin permits glucose to directly suppress pancreatic A cell function

The Journal of clinical investigation, 1991-09, Vol.88 (3), p.767-773

1991

Volltextzugriff (PDF)

Identification of tissue-specific cell death using methylation patterns of circulating DNA

Proceedings of the National Academy of Sciences - PNAS, 2016-03, Vol.113 (13), p.E1826-E1834

2016

Volltextzugriff (PDF)

The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis

The journal of clinical endocrinology and metabolism, 2020-12, Vol.105 (12), p.1-e4406

2020

Volltextzugriff (PDF)

Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes

The Journal of immunology (1950), 2011-08, Vol.187 (4), p.1998-2005

2011

Volltextzugriff (PDF)

Type 1 Diabetes Intervention Trials: What Have We Learned? A Critical Review of Selected Intervention Trials

Clinical Immunology, 2002-08, Vol.104 (2), p.97-104

Greenbaum, Carla J.

2002

Volltextzugriff (PDF)

Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1[frac12] diabetes in patients presenting with type 2 diabetes

Metabolism, clinical and experimental, 2001-09, Vol.50 (9), p.1008-1013

2001

Volltextzugriff (PDF)

Macrophages from High‐Risk HLA‐DQB10201/0302 Type 1 Diabetes Mellitus Patients are Hypersensitive to Lipopolysaccharide Stimulation

Scandinavian journal of immunology, 2002-11, Vol.56 (5), p.522-529

2002

Volltextzugriff (PDF)

Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

Diabetes (New York, N.Y.), 1996-11, Vol.45 (11), p.1631-1634

1996

Volltextzugriff (PDF)

Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study

Diabetes (New York, N.Y.), 1990-05, Vol.39 (5), p.549-556

1990

Volltextzugriff (PDF)

Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

European journal of immunology, 2016-04, Vol.46 (4), p.1030-1046

2016

Volltextzugriff (PDF)

1 – 25 von 746

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(682)
Mit Volltextzugriff
(627)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(732)
Französisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Latent autoimmune diabetes in adults (LADA) should be less latent

NETosis‐associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count

In‐vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes

Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study

Longitudinal monitoring of gene expression in ultra‐low‐volume blood samples self‐collected at home

Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients

Immunomodulation in Type 1 Diabetes by NBI‐6024, an Altered Peptide Ligand of the Insulin B(9−23) Epitope

High frequency of abnormal glucose tolerance in DQA10102/DQB10602 relatives identified as part of the Diabetes Prevention Trial-Type 1 Diabetes

Islet cell antibody-positive relatives with human leukocyte antigen DQA10102, DQB10602: identification by the Diabetes Prevention Trial-type 1

Evaluation of in vivoT cell kinetics: use of heavy isotope labelling in type 1 diabetes

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes

Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes

Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

Intra-islet insulin permits glucose to directly suppress pancreatic A cell function

Identification of tissue-specific cell death using methylation patterns of circulating DNA

The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis

Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes

Type 1 Diabetes Intervention Trials: What Have We Learned? A Critical Review of Selected Intervention Trials

Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1[frac12] diabetes in patients presenting with type 2 diabetes

Macrophages from High‐Risk HLA‐DQB10201/0302 Type 1 Diabetes Mellitus Patients are Hypersensitive to Lipopolysaccharide Stimulation

Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes

Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study

Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

Suchergebnisse filtern